Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma

[1] Fowler NH(2018)RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma J Clin Oncol 36 7500-2481

[2] Morschhauser F(2017)Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone J Clin Oncol : official journal of the American Society of Clinical Oncology 35 2473-1347

[3] Feugier P(2017)Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study Lancet Oncol 18 1338-283

[4] Bouabdallah R(2014)The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review Leuk Res 38 275-2603

[5] Tilly H(2014)International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer J Clin Oncol : official journal of the American Society of Clinical Oncology 32 2595-3465

[6] Palomba ML(2011)Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study J Clini Oncol : official journal of the American Society of Clinical Oncology 29 3457-3386

[7] Thieblemont C(2012)Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score Cancer 118 3377-250

[8] Tilly H(2000)Cancer in the frail patient. A coming epidemic Hematol Oncol Clin North Am 14 235-3872

[9] Gomes da Silva M(2016)Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy Cancer 122 3865-3485

[10] Casasnovas RO(2006)Age and acute myeloid leukemia Blood 107 3481-1138

[1] Fowler NH(2018)RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma J Clin Oncol 36 7500-2481

[2] Morschhauser F(2017)Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone J Clin Oncol : official journal of the American Society of Clinical Oncology 35 2473-1347

[3] Feugier P(2017)Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study Lancet Oncol 18 1338-283

[4] Bouabdallah R(2014)The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review Leuk Res 38 275-2603

[5] Tilly H(2014)International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer J Clin Oncol : official journal of the American Society of Clinical Oncology 32 2595-3465

[6] Palomba ML(2011)Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study J Clini Oncol : official journal of the American Society of Clinical Oncology 29 3457-3386

[7] Thieblemont C(2012)Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score Cancer 118 3377-250

[8] Tilly H(2000)Cancer in the frail patient. A coming epidemic Hematol Oncol Clin North Am 14 235-3872

[9] Gomes da Silva M(2016)Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy Cancer 122 3865-3485

[10] Casasnovas RO(2006)Age and acute myeloid leukemia Blood 107 3481-1138